--- title: Buy Viropil (Dolutegravir/Lamivudine/Tenofovir) 50/300/300mg Pills description: Viropil (Dolutegravir/Lamivudine/Tenofovir Disoproxil Fumarate) 50/300/300mg tablets treat HIV infection. Order from our verified pharmacy for genuine medication and privacy. type: product language: en url: https://liabilis.com/order-viropil-online-en.html availability: in_stock shipping: - type: Standard Airmail price: 10.00 currency: USD area: Worldwide time: 14-21 days - type: Tracked Express price: 30.00 currency: USD area: Worldwide tracking: true time: 5-9 days price_min: 274.99 price_max: 660.99 currency: USD offers: - name: 50/300/300mg x 30 pills price: 274.99 - name: 50/300/300mg x 60 pills price: 495.99 - name: 50/300/300mg x 90 pills price: 660.99 --- # Buy Viropil (Dolutegravir/Lamivudine/Tenofovir) 50/300/300mg Pills Viropil, containing Dolutegravir, Lamivudine, and Tenofovir Disoproxil Fumarate, is a combination antiretroviral therapy for adults managing HIV-1 infection. It suppresses viral load effectively. Available in 50/300/300mg pills from our secure online pharmacy. ## Pricing and Options | Dosage | Pack Size | Price (USD) | Price Per Pill | Status | | :--- | :--- | :--- | :--- | :--- | | **50/300/300mg** | 30 pills | **$274.99** | $9.17 | In Stock | | **50/300/300mg** | 60 pills | **$495.99** | $8.27 | In Stock | | **50/300/300mg** | 90 pills | **$660.99** | $7.34 | In Stock | [Buy Now](https://liabilis.com/order-viropil-online-en.html) ## Introduction Viropil is a fixed-dose combination tablet that contains the three antiretroviral agents dolutegravir, lamivudine, and tenofovir disoproxil fumarate (50 mg/300 mg/300 mg). It belongs to the class of HIV-1 integrase strand transfer inhibitor (INSTI) regimens combined with nucleoside reverse-transcriptase inhibitors (NRTIs). The product is approved for the treatment of adults with HIV-1 infection and is taken once daily. In addition to its primary role in suppressing viral replication, the combination provides a convenient, single-pill option that reduces pill burden and improves adherence. ## Quick Reference Facts **Active Ingredient** : Dolutegravir / Lamivudine / Tenofovir disoproxil fumarate **Form** : Pill - 50 mg / 300 mg / 300 mg **Primary and Off-Label Uses** : • Treatment of HIV-1 infection in adults : • Occasionally used off-label for post-exposure prophylaxis (PEP) under specialist supervision ## What is Viropil? Viropil is the generic version of medications containing the active compound dolutegravir / lamivudine / tenofovir disoproxil fumarate. It is marketed internationally as a single-tablet regimen that delivers the three agents in a fixed dose of 50 mg dolutegravir, 300 mg lamivudine, and 300 mg tenofovir DF. Brand-name equivalents include Triumeq, which was the first commercially available triple-drug tablet of this composition. Because Viropil is a generic product, it must meet the same bioequivalence standards set by regulatory authorities and provides a cost-effective alternative to the brand formulation. The medication is manufactured by licensed pharmaceutical firms that follow Good Manufacturing Practice (GMP) requirements; specific manufacturer details are disclosed on the product label. ## How Viropil Works Dolutegravir inhibits the HIV-1 integrase enzyme, preventing the insertion of viral DNA into the host genome. This action halts a critical step in the HIV replication cycle and leads to a rapid decline in plasma viral load. Lamivudine and tenofovir disoproxil fumarate are nucleoside/nucleotide reverse-transcriptase inhibitors (NRTIs). Both are phosphorylated inside cells to active triphosphate forms that compete with natural nucleotides, causing premature chain termination during reverse transcription. By pairing an INSTI with two NRTIs, Viropil attacks HIV at multiple points, producing synergistic viral suppression and a high barrier to resistance. The tablet is designed for once-daily administration; peak plasma concentrations of dolutegravir occur 2-3 hours after ingestion, while lamivudine and tenofovir reach steady state within 4-5 days. All three components are eliminated primarily via renal excretion (tenofovir) and hepatic metabolism (dolutegravir), allowing predictable dosing in most adults with normal kidney and liver function. ## Conditions Treated with Viropil - **HIV-1 infection (treatment-naïve adults)** Viropil provides potent viral suppression as part of first-line antiretroviral therapy (ART). The INSTI backbone delivers rapid reductions in viral load, while the dual NRTIs maintain long-term suppression and mitigate emergence of resistance. - **HIV-1 infection (treatment-experienced adults with no resistance to study drugs)** For patients switching from other regimens, Viropil offers a simplified once-daily option that maintains efficacy when resistance testing confirms susceptibility. - **HIV-1 infection with concomitant hepatitis B virus (HBV) infection** Tenofovir DF has activity against HBV, allowing Viropil to address both infections simultaneously. Clinical guidelines advise continuation of the tenofovir component to avoid HBV reactivation. ## Is Viropil the Right Medication for You? Viropil is most appropriate for adults who are newly diagnosed with HIV-1 and have no known resistance to dolutegravir, lamivudine, or tenofovir. It is also suitable for patients seeking a single-tablet regimen to simplify daily dosing and improve adherence. Clinical scenarios that favor Viropil include individuals with co-existing HBV infection, because tenofovir DF provides dual antiviral coverage. Contraindications include hypersensitivity to any component of the combination, severe renal impairment (eGFR < 30 mL/min) where tenofovir dosing is not recommended, and patients with active, uncontrolled hepatitis C where drug-drug interaction monitoring is required. Caution is advised in the elderly, pregnant or breastfeeding women, and individuals taking concomitant medications that affect dolutegravir metabolism (e.g., strong inducers of UGT1A1 or CYP3A4). A thorough assessment by a qualified healthcare provider is essential before initiating therapy. ## Buying Viropil from [our online pharmacy](https://liabilis.com/order-viropil-online-en.html) ### Why Choose Our Service? Accessing affordable HIV medication can be challenging when insurance coverage is limited or geographic availability is constrained. Our pharmacy service delivers a reliable solution, enabling patients to obtain Viropil at prices close to wholesale cost while preserving confidentiality. ### Quality & Safety Assurance We partner with licensed international pharmacies to ensure quality and authenticity. Every batch of Viropil is verified against regulatory standards, and only products from GMP-certified manufacturers are dispensed. ### Pricing & Access Because Viropil is a generic formulation, it is offered at a substantially lower price than brand-name equivalents such as Triumeq. [our online pharmacy](https://liabilis.com/order-viropil-online-en.html) makes this cost saving transparent, allowing patients to maintain their treatment without financial strain. ### Discreet Delivery Your order will be packaged in plain, unmarked envelopes and shipped via express delivery typically within 7 days, or by standard airmail in approximately 3 weeks. All personal information is encrypted and handled in compliance with privacy regulations, ensuring a secure and private transaction through our service. ## Use: Dosing, Missed Dose, Overdose - **Standard dosing**: One tablet (50 mg/300 mg/300 mg) taken orally once daily with or without food. - **Missed dose**: If a dose is forgotten and it has been less than 12 hours since the scheduled time, take the missed tablet immediately. If more than 12 hours have passed, skip the missed dose and resume the regular schedule. Do not double-dose. - **Suspected overdose**: Ingesting more than one tablet may increase the risk of renal toxicity from tenofovir and gastrointestinal upset from lamivudine. Seek emergency medical assistance or contact a poison control center promptly. - **Practical precautions**: Avoid concomitant use of nephrotoxic agents (e.g., non-steroidal anti-inflammatory drugs) unless medically indicated. Alcohol does not interact directly but may exacerbate liver enzyme elevations. Patients should not operate heavy machinery if they experience dizziness or severe fatigue after dosing. ## Safety Information ### ⚠️ Who Should Not Take Viropil - Individuals with known hypersensitivity to dolutegravir, lamivudine, tenofovir disoproxil fumarate, or any excipients. - Patients with severe renal impairment (eGFR < 30 mL/min) where tenofovir dosing is contraindicated. - Patients receiving concomitant therapy with didanosine, as the combination can increase the risk of pancreatitis. ### Common Side Effects - **Nausea, diarrhea, and abdominal discomfort** - typically mild and transient; may improve with food. - **Headache** - reported in up to 10 % of users; usually resolves without intervention. - **Insomnia** - can be mitigated by taking the tablet earlier in the day. Management strategies include staying hydrated, adjusting meal timing, and consulting a clinician if symptoms persist beyond two weeks. ### Serious Side Effects (Seek Immediate Medical Help) - **Acute renal failure** - indicated by sudden swelling, reduced urine output, or sharp increase in serum creatinine. - **Severe hepatotoxicity** - manifested by jaundice, dark urine, or persistent elevation of liver enzymes. - **Hypersensitivity reactions** - rash, fever, facial swelling, or difficulty breathing. If any of these events occur, discontinue Viropil and obtain emergency care. ### Drug & Food Interactions - **Antacids containing polyvalent cations (aluminum, magnesium, calcium, iron)** - may reduce dolutegravir absorption; separate dosing by at least 2 hours. - **Rifampin, carbamazepine, phenytoin** - strong inducers of UGT1A1/CYP3A4 can lower dolutegravir levels; dose adjustment or alternative ART is recommended. - **Didanosine** - increased risk of pancreatitis; co-administration is contraindicated. - **Lamivudine/tenofovir with other nephrotoxic drugs** - monitor renal function closely. ## Off-Label and Investigational Uses of Viropil - **Post-exposure prophylaxis (PEP)** - Some clinical protocols have incorporated a dolutegravir-based triple regimen for occupational or sexual exposure to HIV, citing rapid viral suppression. This use remains off-label and should only be pursued under specialist supervision. - **Simplified regimen for treatment-experienced patients with archived resistance** - Small cohort studies suggest that switching to a dolutegravir-containing triple may retain efficacy when resistance patterns are favorable, though formal approval is pending. All off-label applications lack regulatory endorsement; patients must discuss potential risks and benefits with a qualified healthcare provider before use. ## Storage & Handling - Store tablets at controlled room temperature (15 °C-30 °C). - Protect from excessive moisture and direct sunlight. - Keep the container tightly closed and out of reach of children. - Do not use tablets past the expiration date printed on the label. - For safe disposal, return unused medication to a pharmacy take-back program or follow local hazardous waste guidelines. ## Frequently Asked Questions **Practical Use & Lifestyle** - **Can I travel internationally with Viropil?** Yes. Carry the medication in its original packaging with a copy of the prescription or a physician’s letter, as some countries require documentation for import of antiretrovirals. - **Will taking Viropil with a high-protein meal alter its effectiveness?** Dolutegravir absorption can be modestly reduced by calcium-rich foods, but the impact is not clinically significant for most patients. If you routinely consume large amounts of dairy, consider separating the dose by at least two hours. **Product & Formulation Details** - **What does a Viropil tablet look like?** The tablet is round, film-coated, and typically white to off-white. Imprints may include the dosage code “50/300/300” and the brand identifier “VIRO”. Appearance can vary slightly between manufacturing batches. - **Are there any inactive ingredients I should be aware of?** Common excipients include microcrystalline cellulose, lactose monohydrate, magnesium stearate, and hypromellose. Patients with severe lactose intolerance should discuss alternatives with their clinician. **Regulatory & Safety Nuances** - **Is Viropil approved for use during pregnancy?** Dolutegravir-based regimens are classified as pregnancy category B by the WHO, meaning no evidence of fetal risk in animal studies and limited human data. Lamivudine and tenofovir are also considered relatively safe. Nevertheless, treatment decisions in pregnancy require obstetric and infectious-disease specialist input. - **Will Viropil appear on standard drug-testing panels for athletes?** Antiretrovirals are not typically screened in routine sport doping tests. However, specific antiretroviral screening may be requested in certain circumstances; consult the testing authority for clarification. - **Can I obtain Viropil without a prescription in my country?** The availability of prescription-only medicines varies by jurisdiction. In most regions, Viropil requires a valid prescription from a licensed prescriber. **Scientific & Clinical Curiosity** - **How does the resistance barrier of dolutegravir compare with older INSTIs?** Dolutegravir has a higher genetic barrier to resistance than raltegravir and elvitegravir, owing to its stronger binding affinity to the integrase active site. This translates into lower rates of resistance emergence in clinical trials. - **What major clinical trial supported the approval of this combination?** The FLAMINGO and SINGLE studies demonstrated non-inferior efficacy of dolutegravir-based triple therapy compared with standard efavirenz-based regimens, leading to regulatory approval for treatment-naïve adults. ## Glossary **Integrase Strand Transfer Inhibitor (INSTI)** : A class of antiretroviral drugs that block the HIV integrase enzyme, preventing viral DNA from integrating into the host genome. **Nucleoside Reverse-Transcriptase Inhibitor (NRTI)** : Compounds that mimic natural nucleosides, become incorporated into viral DNA, and terminate chain elongation during reverse transcription. **Bioequivalence** : Demonstration that a generic product delivers the same amount of active ingredient into the bloodstream as the reference brand, within an accepted range of variability. **eGFR (estimated Glomerular Filtration Rate)** : A calculated metric used to assess kidney function; essential for dosing tenofovir-containing regimens. **Hypersensitivity Reaction** : An immune-mediated adverse response that can manifest as rash, fever, swelling, or respiratory difficulty. ## Disclaimer The information provided about **Viropil** is for general knowledge only. It does not replace professional medical consultation. All treatment decisions, including those regarding off-label use, should be made under the supervision of a qualified healthcare provider. We assume all readers are responsible adults capable of making informed decisions about their health. [our online pharmacy](https://liabilis.com/order-viropil-online-en.html) offers access to **Viropil** for individuals who may have limited availability through traditional pharmacies, prescription-based insurance schemes, or who are seeking affordable generic alternatives. Always consult your doctor before starting, changing, or discontinuing any medication.